Know Cancer

or
forgot password

Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma


N/A
18 Years
N/A
Open (Enrolling by invite only)
Both
High Grade Glioma

Thank you

Trial Information

Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma


Combination temozolomide and radiation significantly prolongs survival compared with
radiation alone and has become standard treatment for glioblastoma multiforme (GBM).
Response assessment in GBM is difficult as a result of the frequent occurrence of early
imaging changes indistinguishable from tumor progression, termed pseudoprogression. The
majority of patients remain clinically stable. It is often unclear whether current therapy
should be maintained or second-line therapy initiated. The incidence of pseudoprogression
after concurrent chemoradiation is15%to 30%. A potential mechanism of pseudoprogression is
that radiation-induced vascular changes may lead to focal transient increase in gadolinium
enhancement. Dynamic contrast-enhanced (DCE) MR imaging provides a noninvasive means for
quantifying tumor vascular properties.


Inclusion Criteria:



- Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic
astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the
patients show the measurable enhancing portion (1 cm in the long diameter according
to the RANO criteria) in the immediate f/up MRI after CCRT.

Exclusion Criteria:

- Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic
astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the
patients do not show the measurable enhancing portion (1 cm in the long diameter
according to the RANO criteria) in the immediate f/up MRI after CCRT.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Permeability Map to Distinguish Progression From Pseudoprogression in High-grade glioma

Outcome Time Frame:

2year

Safety Issue:

No

Principal Investigator

SeungHong Choi, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Seoul National University Hospital(Radiology)

Authority:

Korea: Institutional Review Board

Study ID:

H-1108-032-372

NCT ID:

NCT01499823

Start Date:

December 2011

Completion Date:

August 2013

Related Keywords:

  • High Grade Glioma
  • Permeability Map
  • High-Grade Glioma
  • Glioma

Name

Location